Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMERICAN BIOMED RESUMING OMNICATH CLINICAL TRIALS

This article was originally published in The Gray Sheet

Executive Summary

AMERICAN BIOMED RESUMING OMNICATH CLINICAL TRIALS after a one- year hiatus resulting from an FDA objection to a modification to the atherectomy device. American BioMed obtained its original investigational device exemption to study OmniCath in peripheral arteries in June 1991 ("The Gray Sheet" Sept. 16, 1991 p. 20). However, FDA asked the firm to halt its study in August 1992 after learning that the device design had been modified. The agency requested animal data on the new device, and the firm submitted the information to FDA in a May 6 supplement to the IDE. The agency approved the supplement on July 22, clearing the way for studies to recommence. Under the original IDE, two patients were treated with the first OmniCath design and one patient was treated with the revised device, which is designed to improve torque. The IDE supplement allows an additional ten patients to be studied. Clinical trial sites include Conroe Regional Medical Center north of Houston, Baylor University Hospital in Dallas and possibly Methodist Hospital in Houston, pending the institutional review board's approval. On July 23, the Canadian Health Protection Board cleared OmniCath studies in arterial venous dialysis grafts. The approval allows the device to be studied in up to 100 patients, the first ten of which are expected to be treated at Toronto General Hospital. Clearance to begin studies in Canada for peripheral use is anticipated in three to four weeks, the company says.

You may also be interested in...



Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.

Public Health Threat For EU Patients If IVDR Implementation Issues Remain Unaddressed

The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.

AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023

Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel